Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy

Open Access
Publisher Website
Google Scholar
Abstract
Between April 1981 and June 1985, 195 patients with ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) Stages IIB, IIC, III, and IV, entered a trial that consisted of surgery and chemotherapy with cisplatin (P) and melphalan (PAM) with or without hexamethylmelamine (HexaPAMP or PAMP regimens) every 4 weeks for 6 cycles. Because the intent was to study the outcome by treatment after evaluation of first‐line chemotherapy, patients were evaluable only if the response was assessed by a second‐look operation or if measurable disease progression was documented. One hundred fifty‐eight patients (81%) were evaluable for response. Forty‐five (28%) achieved pathologically confirmed complete remissions (pCR), and 24 of these patients received whole‐abdominal radiation (WAR) for consolidation of response. Five patients with complete remission after WAR relapsed, as did nine of the 21 with complete remission who had not undergone WAR. The 3‐year time to progression percentage (TTP ± SE) from second‐look operation was 70% ± 7% for all patients who achieved pCR, 83% ± 8% for those who received WAR, and 49% ± 15% for those who did not receive WAR (this was not a randomized comparison). The 3‐year TTP percentage for the 49 partial responders was 21% ± 6%, identical for the 19 who had WAR and the 30 who had no radiation therapy. Additional or alternative methods for consolidation of pCR are needed since patients continue to relapse despite optimal initial response to therapy.